Physician profile
Jonathan A Storey
NPI 1659568012
$15,174.84
in general payments reported to CMS, 2019-2025
60 companies · $2,571 in 2025
The $2,571 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,635 · 2020: $981 · 2021: $2,495 · 2022: $2,709 · 2023: $1,925 · 2024: $1,859 · 2025: $2,571.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,306 · Education: $48.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,305.75 |
| Education | $48.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Varian Medical Systems, INC. | $1,605.00 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $1,371.99 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $1,258.37 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Pfizer INC. | $969.53 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $796.28 | 2019-2025 | Imfinzi, Calquence, Enhertu |
| Takeda Pharmaceuticals U.S.A., INC. | $657.95 | 2019-2025 | Iclusig, Ninlaro, Fruzaqla |
| Genentech USA, INC. | $588.09 | 2019-2025 | Venclexta, Tecentriq, Polivy |
| Janssen Biotech, INC. | $549.64 | 2019-2025 | Darzalex, Talvey, Erleada |
| E.R. Squibb & Sons, L.L.C. | $505.84 | 2019-2025 | Opdivo, Opdualag |
| Seagen INC. | $465.02 | 2019-2023 | Padcev, Tukysa, Adcetris |
| Abbvie INC. | $443.88 | 2019-2025 | Venclexta |
| Lilly USA, LLC | $385.68 | 2019-2025 | Verzenio, Jaypirca, Retevmo |
| Daiichi Sankyo INC. | $374.57 | 2019-2025 | Enhertu, Injectafer, Datroway |
| Amgen INC. | $365.33 | 2019-2022 | |
| Incyte Corporation | $341.03 | 2021-2025 | Jakafi, Pemazyre, Monjuvi |
Show all 60 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $303.28 | 2019-2025 | Opdualag, Pomalyst, Reblozyl |
| Gilead Sciences, INC. | $266.83 | 2019-2025 | Trodelvy |
| Eisai INC. | $264.03 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $249.78 | 2019-2025 | |
| Genzyme Corporation | $233.20 | 2019-2025 | |
| Array Biopharma INC | $228.92 | 2022-2025 | Braftovi, Mektovi, Tukysa |
| Pharmacyclics LLC, An Abbvie Company | $188.99 | 2019-2023 | Imbruvica, Epkinly |
| Regeneron Healthcare Solutions, INC. | $168.71 | 2019-2025 | Libtayo |
| Astellas Pharma US INC | $162.66 | 2019-2025 | Veozah, Xtandi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $162.05 | 2019-2025 | |
| Pharmacosmos Therapeutics INC. | $149.99 | 2022-2025 | Monoferric |
| Stemline Therapeutics INC. | $137.15 | 2022-2025 | Orserdu |
| Beigene USA, INC. | $122.70 | 2022-2025 | Brukinsa |
| Kite Pharma, INC. | $120.11 | 2020-2025 | Yescarta |
| Exelixis INC. | $116.18 | 2019-2025 | Cabometyx |
| Sobi, INC | $113.17 | 2022-2025 | |
| Blueprint Medicines Corporation | $113.01 | 2021-2023 | Ayvakit |
| Kyowa Kirin, INC. | $105.00 | 2019-2024 | Poteligeo |
| Sumitomo Pharma America, INC. | $97.69 | 2023-2025 | Orgovyx |
| Glaxosmithkline, LLC. | $89.32 | 2021-2025 | Ojjaara, Jemperli, Zejula |
| Alexion Pharmaceuticals, INC. | $87.38 | 2019-2024 | Ultomiris |
| Karyopharm Therapeutics INC. | $80.08 | 2020-2023 | Xpovio |
| Emd Serono, INC. | $69.42 | 2019-2022 | |
| Myriad Genetic Laboratories, INC. | $67.55 | 2021-2023 | Bracanalysis Cdx |
| Janssen Pharmaceuticals, INC | $58.00 | 2019 | |
| Myovant Sciences INC. | $55.08 | 2021-2022 | |
| Beone Medicines USA, INC. | $55.01 | 2025 | Brukinsa |
| Tersera Therapeutics LLC | $54.78 | 2025 | Quzyttir |
| Deciphera Pharmaceuticals INC. | $54.07 | 2021-2025 | Qinlock, Romvimza |
| Servier Pharmaceuticals LLC | $53.63 | 2024-2025 | |
| Aveo Pharmaceuticals, INC. | $51.36 | 2025 | |
| Jazz Pharmaceuticals INC. | $45.22 | 2022 | |
| Puma Biotechnology, INC. | $43.17 | 2020-2024 | |
| Progenics Pharmaceuticals, INC. | $38.98 | 2022-2024 | |
| Rigel Pharmaceuticals, INC. | $36.45 | 2019-2022 | |
| Epizyme, INC. | $36.40 | 2021 | |
| Tolmar Pharmaceuticals, INC. | $36.07 | 2019 | |
| Global Blood Therapeutics, INC. | $30.39 | 2021-2022 | |
| Dova Pharmaceuticals | $29.87 | 2020-2021 | |
| Pharmaessentia USA Corporation | $25.24 | 2025 | Besremi |
| Caris Mpi, INC. | $22.07 | 2025 | Mi Cancer Seek |
| Fresenius Kabi USA, LLC | $21.50 | 2025 | |
| Clovis Oncology, INC. | $21.42 | 2019-2021 | |
| Tactile Systems Technology INC | $18.97 | 2025 | Flexitouch Plus, Nimbl |
| Immunomedics, INC. | $11.76 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Storey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.